Cargando...
Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of...
Guardado en:
| Publicado en: | EJNMMI Res |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer Berlin Heidelberg
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6365580/ https://ncbi.nlm.nih.gov/pubmed/30725219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-019-0484-y |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|